Skip to main content
Premium Trial:

Request an Annual Quote

This Week in JAMA: Apr 27, 2011

Premium

In JAMA this week, a team of researchers in Massachusetts led by scientists at the Dana-Farber Cancer Institute present findings from a study on the associations between alternations in the CTNNB1 protein, body-mass index, and physical activity in the survival of patients with colorectal cancer. To test their hypothesis that CTNNB1 activation modifies the prognostic associations of BMI and physical activity post-diagnosis, the researchers evaluated CTNNB1 localization in 955 colorectal cancer patients between 1980 and 2004. In patients with a BMI greater than 30, positive status for nuclear CTNNB1 was associated with significantly better colorectal cancer-specific survival as well as overall survival, the authors write. "Among obese patients only, activation of CTNNB1 was associated with better colorectal cancer–specific survival and overall survival. Postdiagnosis physical activity was associated with better colorectal cancer–specific survival only among patients with negative status for nuclear CTNNB1," the team adds. "These molecular pathological epidemiology findings suggest that the effects of alterations in the WNT-CTNNB1 pathway on outcome are modified by BMI and physical activity."

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more